FuseBio Presents New Data at AACR: Targeting a Functionally-Selective IL-18 (F-18) to PD-1: A Next Generation Checkpoint Inhibitor with Enhanced Anti-Tumor Activity

FuseBio's unique attenuation mechanism renders IL-18, a functionally selective IL-18, resistant to IL-18BP and 1 million percent less active in circulation and yet still retain nearly full activity when targeted to PD-1+/IL-18R+ cells, the key functional immune cells in tumors. It is designed to retain full activity of PD-1 checkpoint blockade and simultaneously deliver a functionally selective IL-18 (F-18) to preserve and enhance the anti-tumor activity of immune cells. - April 09, 2024 - Fuse Biotherapeutics

MENADNA and ProPhase Labs' (NASDAQ: PRPH) Wholly-Owned Subsidiary, Nebula Genomics, Announce Strategic Partnership to Enhance Genomic Testing in Jordan, Oman and Iraq

MENADNA and ProPhase Labs' (NASDAQ: PRPH) Wholly-Owned Subsidiary, Nebula Genomics, Announce Strategic Partnership to Enhance Genomic Testing in Jordan, Oman and Iraq

MENADNA Inc., has entered into an exclusive partnership with ProPhase Labs' subsidiary, Nebula Genomics, aiming to advance genomic testing in Jordan, Oman, and Iraq. This collaboration will leverage Nebula Genomics' advanced sequencing technologies and MENADNA's bioinformatics capabilities to improve the quality and relevance of genomic data in these historically underserved regions. - March 18, 2024 - MENADNA

Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies

Cayman Chemical introduces the latest addition to the company’s portfolio of lipid nanoparticle (LNP) research tools for academic, pharma, and biotech researchers worldwide. The LipidLaunch™ product line helps researchers pursue LNPs for the delivery of nucleic acid therapies in untold health applications, ranging from vaccine development to cancer and cell or gene therapies. - February 22, 2024 - Cayman Chemical Company

Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report

Sponsor Outsourcing Dollars May Shift to Clinical Site Networks, Transforming the CRO Relationship - February 13, 2024 - Life Science Strategy Group, LLC

Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials Report

New Market Research Shows Different Patient Preferences for Electronic Diaries - January 31, 2024 - Life Science Strategy Group, LLC

New Sustainable Lyophilization Technology Uses Supercritical CO2

The Thar group of companies have been using CO2 for extraction, purification, particle design and encapsulation for many years but recent developments point to a need for sustainable methods for drying APIs, intermediates, excipients and biologics at relatively low temperatures. 'Big Pharma' has depended on Thar for SFC tools in drug discovery but lyophilization will likely be used in manufacturing too. - January 28, 2024 - Thar Process, Inc.

Impact of the In Vitro Diagnostic Regulation on Clinical Trials in the EU and CRO Outsourcing Report

IVDR Delays Driving Trial Sponsors to Actively Seek Alternative Site and CRO Outsourcing Strategies - January 17, 2024 - Life Science Strategy Group, LLC

Zifo Named Fastest Growing Technology Company in Deloitte Technology Fast 50 India 2023

Zifo has bagged this award for the 11th consecutive time. - December 20, 2023 - Zifo

Cayman Chemical Introduces a New Tool to Study Protein-Lipid Interactions

Cayman LipiDOT Strips™ are a simple tool for the rapid identification of protein-lipid interactions. Researchers can screen a protein of interest against 22 biologically relevant lipids in one assay in a single day at a lower price compared with existing commercial options. - October 04, 2023 - Cayman Chemical Company

Cayman and Navinci Announce Strategic Partnership, Expanding Access to Next-Generation Tools for Spatial Proteomics

Cayman and Navinci have partnered to bring next-generation proximity ligation-based solutions for spatial proteomics to US and Canada-based researchers. - July 13, 2023 - Cayman Chemical Company

PharmStars Announces Spring 2023 Accelerator Graduates: 13 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program

PharmStars Announces Spring 2023 Accelerator Graduates: 13 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program

PharmStars, the pharma-focused accelerator for digital health startups, announces that 13 startups have graduated from its Spring 2023 program focused on “Innovations in Women’s Health or Health Equity.” The graduating startups successfully completed PharmaU, PharmStars’ 10-week program. PharmaU culminated with a Showcase Event, held in Boston in May, that brought together the participating startups and PharmStars’ innovation-minded pharma members. - June 20, 2023 - PharmStars

International LabAutomation Day is June 21

Celebrating Lab Automation; Laboratory automation refers to the use of technology, equipment, and software to streamline and optimize laboratory processes and operations. It involves automating repetitive tasks, data collection and analysis, sample handling, and other activities in a laboratory setting. By leveraging various automated systems, laboratories can enhance efficiency, accuracy, reproducibility, and throughput while reducing human error and the time required to perform experiments. - June 20, 2023 - Laboratory Robotics Interest Group (LRIG)

PharmStars Announces “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface” Theme for its Fall 2023 Accelerator

PharmStars Announces “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface” Theme for its Fall 2023 Accelerator

PharmStars, the pharma-focused accelerator for digital health startups, is accepting applications for its Fall 2023 cohort around the theme “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface.” The cohort is open to startups with digital health solutions that pharma can use to innovate therapeutic supply chain management, medication delivery, or the patient-drug experience for small molecules, biologics, or advanced therapies. Applications are due July 10, 2023. - June 06, 2023 - PharmStars

New Research Benchmarks Biopharmaceutical Perceptions of Global CRO Thought Leadership

Landmark Research Analyzes Perspectives of US and EU Biopharma C-Suite, Clinical Operations and Medical/Regulatory Affairs Professionals on Global CRO Thought Leadership. - June 01, 2023 - Life Science Strategy Group, LLC

PharmStars Announces Spring 2023 Startup Showcase Event Underway

PharmStars Announces Spring 2023 Startup Showcase Event Underway

PharmStars, the pharma-focused accelerator for digital health startups, announces that its fourth Showcase Event begins May 16, 2023. The Showcase is the culmination of the Spring 2023 10-week accelerator program. At the Showcase, each startup in the fourth cohort makes a formal presentation to and meets individually with PharmStars’ pharma members. The theme of the Spring 2023 program is digital innovations in women’s health or health equity. - May 16, 2023 - PharmStars

New Traceable Opioid Material® Kit Expands Coverage to Other Emerging Drugs of Concern in Seized Samples and Toxicological Casework

Cayman Chemical and the Centers for Disease Control and Prevention (CDC) have released a new addition to the Traceable Opioid Material® Kits (TOM Kits®) product line that expands testing laboratory capabilities beyond synthetic opioids to include additional emerging drugs of abuse that are commonly found as co-drugs in fentanyl-containing samples. - April 30, 2023 - Cayman Chemical Company

New Research on Decentralized Clinical Trial (DCT) Strategies to Boost Patient Diversity

Current and Future Clinical Trial Participants Link Enhanced Diversity and Inclusion of Underrepresented Patient Populations to DCT - March 29, 2023 - Life Science Strategy Group, LLC

New Research Identifies Latest Clinical Development and CRO Outsourcing Trends in China

Groundbreaking Research Explores the Chinese Innovative Biopharmaceutical Clinical Development Market, CRO Outsourcing and Future Growth with Over 100 Chinese Biopharma Professionals - March 15, 2023 - Life Science Strategy Group, LLC

Zifo R&D Solutions Announces Acquisition of beyontics GmbH

Zifo, a leading global specialist scientific informatics services provider, announces the acquisition of beyontics™. A scientific service provider, beyontics has extensive experience in selecting, configuring, optimizing, and supporting Chromatography Data Systems (CDS), particularly the... - January 19, 2023 - Zifo

PharmStars Announces Fall 2022 Accelerator Graduates: 11 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program

PharmStars Announces Fall 2022 Accelerator Graduates: 11 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program

PharmStars, the pharma-focused accelerator for digital health startups, announces the graduation of 11 startups from its Fall 2022 program focused on “Innovations in Real-World Evidence.” The graduating startups successfully completed PharmaU, PharmStars’ 10-week education, and mentoring program. PharmaU culminated with a Showcase Event--held in Boston in early November--that brought together the participating startups and PharmStars’ seven innovation-minded pharma members. - December 08, 2022 - PharmStars

PharmStars Announces “Innovations in Women’s Health and Health Equity” Theme for Spring 2023 Accelerator

PharmStars Announces “Innovations in Women’s Health and Health Equity” Theme for Spring 2023 Accelerator

PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its Spring 2023 cohort with the theme “Digital Innovations in Women’s Health and Health Equity.” Startups with digital innovations that promote more equitable, inclusive healthcare for underserved population or focused on women’s health (e.g., breast, ovarian, and cervical cancer; gynecological conditions; osteoporosis; menopausal, hormonal, and reproductive conditions) are welcome to apply. - December 05, 2022 - PharmStars

Prosel Bioscience Becomes One Cell Foods and Names Dr. Scott Jenkins Its New CEO

Prosel Bioscience Becomes One Cell Foods and Names Dr. Scott Jenkins Its New CEO

One Cell Food, Inc will focus on scaling its proprietary bioreactor design to commercialize developed strains for its first food product by early 2023. As the new CEO, Dr. Scott Jenkins will lead the operation and fundraising efforts. - November 17, 2022 - One Cell Foods, Inc.

PharmStars Announces Fall 2022 Startup Showcase Event

PharmStars Announces Fall 2022 Startup Showcase Event

PharmStars, the pharma-focused accelerator for digital health startups, announces that its Fall 2022 Showcase Event will begin on November 8, 2022. The Showcase is the culmination of a 10-week startup accelerator program. At the Showcase Event, startups will make formal presentations to and meet... - November 08, 2022 - PharmStars

Pharma/Vaccine Exec Brad Thompson Joins Fuld & Company as Advisory Board Member

Pharma/Vaccine Exec Brad Thompson Joins Fuld & Company as Advisory Board Member

Fuld & Company welcomes Pharma/Vaccine Exec Brad Thompson as an Advisory Board Member. Brad brings over twenty years of experience building franchise and brand strategies in the vaccine and pharmaceutical space. He will be an instrumental member of Fuld's HLS team to help propel the success of the company's pharma and biotech clients. - November 03, 2022 - Fuld & Company

New Decentralized Clinical Trial (DCT) Patient Satisfaction and Participation Report

800 Current and Future Clinical Trial Participants Link Satisfaction and Willingness to Participate with Decentralized Strategies - September 21, 2022 - Life Science Strategy Group, LLC

Serpin Pharma Awarded Competitive NCI Grant for SP16

Serpin Pharma Awarded Competitive NCI Grant for SP16

The National Cancer Institute awarded Serpin Pharma a $400,000 competitive R43 grant for the Pre-clinical validation of phase II peptide LRP-1 agonist to treat and prevent chemotherapy-induced peripheral neuropathy. The Principal Investigators are Serpin Pharma's CEO and Executive Chairperson, Dr. - September 20, 2022 - Serpin Pharma, LLC

CABRI Announces Call for Proposals on Specialized Pro-Resolving Mediator Analytical Methods

The Cayman Biomedical Research Institute (CABRI) is offering research grants in amounts up to $100,000 to support essential research on specialized pro-resolving mediator (SPM) analytical methods. - August 26, 2022 - Cayman Chemical Company

Deadline Extended: CABRI Announces Undergraduate Fellowships and Scholarship Program

The Cayman Biomedical Research Institute (CABRI) is accepting applications from undergraduate students who have been offered an unpaid laboratory research position under an accredited principal investigator. Applications will be accepted from August 22 until September 18, 2022. - August 26, 2022 - Cayman Chemical Company

Peptineo, LLC Selected by EPA to Provide EPA Nationwide Coverage for Point of Care (POC) COVID-19 Testing

The Environmental Protection Agency (EPA), Cincinnati Acquisition Division (CAD), has awarded Peptineo LLC, an emerging aerospace, health services, and defense solutions company, a three-year Blanket Purchase Agreement (BPA) to support a comprehensive COVID-19 testing program in support of the... - August 07, 2022 - Peptineo

PharmStars Announces Spring 2022 Accelerator Graduates: 11 Digital Health Startups Have Successfully Completed PharmStars’ Pharma-Focused Accelerator Program

PharmStars Announces Spring 2022 Accelerator Graduates: 11 Digital Health Startups Have Successfully Completed PharmStars’ Pharma-Focused Accelerator Program

PharmStars, the pharma-focused accelerator for digital health startups, announces the graduation of 11 startups from its Spring 2022 program. The graduates successfully completed the 10-week PharmaU program, which culminated with the Showcase Event held June 8-10 in Boston. The Showcase Event brought together the participating startups and PharmStars’ seven innovation-minded pharma members. - July 12, 2022 - PharmStars

PharmStars Announces “Innovations in Real-World Evidence” Theme for Fall 2022 Accelerator

PharmStars Announces “Innovations in Real-World Evidence” Theme for Fall 2022 Accelerator

PharmStars, the pharma-focused accelerator for digital health startups, announces it is now accepting applications for its Fall 2022 cohort with the theme, “Innovations in Real-World Evidence.” - June 15, 2022 - PharmStars

PharmStars Announces Showcase Pitch Event for Spring 2022 Cohort

PharmStars Announces Showcase Pitch Event for Spring 2022 Cohort

PharmStars, the pharma-focused accelerator for digital health startups, announces the start of its Showcase Event on June 8, 2022. The digital health startups that participated in the 10-week accelerator program will make formal presentations to, and answer questions from, the pharma members of PharmStars. All of PharmStars’ seven members are participating in the Showcase Event. - June 08, 2022 - PharmStars

Dr. Claudia C. Cotca of C3 Think Tank Appointed as Advisor Chair of Advanced Technology Academic Research Center (ATARC) on Digital AI & Data Analytics Warfighter Health

Dr. Claudia C. Cotca of C3 Think Tank appointed as Advisor Chair of Advanced Technology Academic Research Center (ATARC) on Digital AI & Data Analytics Warfighter Health. Together with leadership and military health experts, stakeholders and program officers, Dr. Claudia C Cotca will help support and contribute to the scope and mission of ATARC’s Warfighter Health in incorporating responsibly artificial intelligence in military medicine. - April 13, 2022 - C3 Think Tank

PharmStars Now Accepting Applications for Spring 2022 Accelerator Program; Startups with Digital Innovations in Neurological Disease Are Welcome to Apply

PharmStars Now Accepting Applications for Spring 2022 Accelerator Program; Startups with Digital Innovations in Neurological Disease Are Welcome to Apply

PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its spring 2022 cohort with the theme, “Digital Innovations in Neurological Disease.” - January 04, 2022 - PharmStars

Global Regenerative Academy Announces Prof. Tahsin Beyzadeoglu as President

Global Regenerative Academy Announces Prof. Tahsin Beyzadeoglu as President

Global Regenerative Academy, independent subsidiary of the Global Regenerative Group Inc., has new board leadership. GRA President is now Prof. Tahsin Beyzadeoglu as announced during the opening Ceremony of GRC Dubai 2021 (November 19-21, 2021) by Mr. Mihail Blagoev (GRG Inc. VP) after being elected by the Scientific Board. - December 21, 2021 - Global Regenerative Group

PharmStars Announces 2021 Accelerator Graduates

PharmStars Announces 2021 Accelerator Graduates

12 digital health startups have successfully completed PharmStars’ inaugural 10-week pharma-focused accelerator program. - December 08, 2021 - PharmStars

PharmStars Announces Showcase Event for Inaugural Class

PharmStars Announces Showcase Event for Inaugural Class

PharmStars, a pharma-focused accelerator for digital health startups, announces the start of its 2021 Showcase Event. At the Showcase Event, the 12 startups in the accelerator’s current cohort will pitch their digital health solutions to PharmStars’ pharma members. The startups and pharma members will also have the opportunity to meet privately to discuss potential partnership opportunities. - November 17, 2021 - PharmStars

PharmStars Welcomes Sumitovant Biopharma as Its Newest Member

PharmStars Welcomes Sumitovant Biopharma as Its Newest Member

PharmStars, the only pharma-focused, member-based accelerator for digital health startups, is pleased to announce that Sumitovant Biopharma has become its newest pharma member, joining existing members including Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk. PharmStars focuses on bridging the "pharma-startup gap." PharmStars provides startups with education and mentoring to help them engage with pharma as clients and partners. - November 03, 2021 - PharmStars

OmeCare and Hillsborough City School District Renew Partnership for Student and Faculty COVID-19 PCR Testing

Partnership helps district ensure safety standards and meet COVID-19 testing protocols for the 2021-2022 school year. - October 16, 2021 - OmeCare

OmeCare and LifeSite Announce COVID-19 Testing Solution Partnership

The partnership provides a turnkey approach for workplaces, schools, major conventions and other group events looking to ensure safety and meet governmental mandates for students, staff, employees and event participants. - October 01, 2021 - OmeCare

Cayman Chemical Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration

The National Institute of Dental and Craniofacial Research has awarded Cayman Chemical with a $1,700,500 grant to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage... - September 19, 2021 - Cayman Chemical Company

Scientists at AbboMax, Inc. Developed the New Panels of Monoclonal Antibodies to Study B- and T-Cell Lymphomas

Lymphoma is a malignant transformation of either B or T cells or their subtypes. All lymphoma subtypes combined are the seventh most common cancer in the United States. The B-cell lymphomas are types of lymphoma affecting B cells. About 85% of lymphomas are of B-cell origin. T-cell lymphomas are lymphomas that affect T cells. AbboMax has developed the new panels of monoclonal antibodies to study B- and T-cell lymphomas. - September 03, 2021 - AbboMax, Inc.

Reverie Psychedelics and Indiana Health Group Partner to Develop World-Class Psychedelic Research Center

Reverie Psychedelics and Indiana Health Group Partner to Develop World-Class Psychedelic Research Center

Reverie Psychedelics (Reverie), a leading and rapidly growing psychedelic – assisted psychotherapy clinic and research organization, has further expanded its footprint and capabilities by partnering with Indiana Health Group (IHG), the largest provider of psychiatric and mental health and... - August 05, 2021 - Reverie Psychedelics

Foxx Life Sciences Celebrates Major Expansion

Foxx Life Sciences celebrates two new manufacturing facilities in Londonderry, New Hampshire and Hyderabad, India. The new locations add four additional SUT (Single Use Technologies) Cleanrooms that will allow Foxx to meet the high demands of their biotechnology and biopharmaceutical customers. New... - August 04, 2021 - Foxx Life Sciences

GRG Announces 2021 Regenerative Medicine Congress in Dubai UAE

GRG Announces 2021 Regenerative Medicine Congress in Dubai UAE

The 2nd Global Regenerative Medicine Congress will be held in Dubai 9-11 September 2021. Registration is now open. Global Regenerative Academy is a world-renowned medical society scientifically studying the clinical application of biological products in the human body. Regenerative Medicine treatments using biological products have been used to slow down the natural aging process, treat a variety of pathologies and improve the quality of life of patients. - June 28, 2021 - Global Regenerative Group

Updated Findings of COVID-19 Impact on Biopharmaceutical Industry & CRO Outsourcing Report

2021 Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO Outsourcing and Changes Since 2020 - May 25, 2021 - Life Science Strategy Group, LLC

Cayman Develops Powerful, New Multiplex ELISA for Autoantibody Detection

Cayman Chemical's new Q-Plex™ Autoantibody Detection 10-Plex Panel, developed in collaboration with Quansys Biosciences, offers standardized, multiplex capabilities for the concurrent analysis of ten prominent analytes associated with rheumatoid arthritis or other autoimmune diseases. This... - May 16, 2021 - Cayman Chemical Company

Temperatures Are Rising – It's Time to Check Your Cooling Towers

As Texas and other parts of the country start to heat up, cooling towers will be in full use. Hyperion Biotechnology offers Legionella testing to monitor for bacteria growth to help reduce the risk of spread from cooling towers. - April 21, 2021 - Hyperion Biotechnology, Inc.

GeneThera, Inc. Wastewater Testing: a Way to Better Control the COVID-19 Pandemic

The global COVID-19 pandemic has demonstrated that neither current systems nor related technologies are capable of preventing or even successfully controlling the spread of zoonotic infectious agents. One of the prominent features of these infectious organisms is their ability to infect both people... - March 30, 2021 - GeneThera Inc.

AbboMax Introduces a Panel of Monoclonal and Polyclonal Anti-Connexin Antibodies

AbboMax introduces a panel of monoclonal and polyclonal anti-connexin antibodies. There are 21 different types of connexins which are known to exist in humans and 20 types in mice. Their abnormal expression and function are associated with human hereditary diseases. AbboMax has been developing & manufacturing high performance immunoassay reagents for many years in California. - March 15, 2021 - AbboMax, Inc.

Press Releases 1 - 50 of 1,227